[ Sino Biological raises $29.41M in Series A ]
Sino Biological has raised $29.41 million in Series A funding.
Founded in 2007, Sino Biological is engaged in the research and development of recombinant protein and antibody reagents for the treatment of cancer and arthritis.
The products can be used to treat a number of diseases such as lung cancer, colorectal cancer, lymphoma, arthritis and Hemophilia.
|City||Beijing, Beijing Municipality|
|Founder / CEO||Liangzhi Xie|
|Investors||Qiming Venture Partners|